Quickly detect multiple antigens in a single tissue section to gain clear understanding of the microenvironment without compromising samples. To serve your multiplex research needs, Bethyl introduces IHC PathPlex™ panels to profile the complex tumor microenvironment. Each antibody has been validated for IHC and utilized in a multiplex format by our own scientists via proprietary processes to ensure the highest quality.
T-cells are crucial to the body’s immune response to cancer, both endogenously and following therapeutic intervention. A T-cell marker panel that can identify subsets of tumor-associated T-cells allows scientists to identify and target subpopulations of T-cells playing unique roles in the immune response against a tumor. Bethyl's portfolio consists of polyclonal and monoclonal antibodies, including new recombinant rabbit monoclonal antibodies.
Simplified Development of Seven-Color Multiplex Immunohistochemistry-Immunofluorescence (mIF) Panels
With the advancement of immunotherapeutics, the need to understand the tumor microenvironment has never been more pressing. Recent advances in mIF and multispectral imaging facilitate accurate simultaneous analysis of multiple tissue markers.
Trial sizes are ideal for comparisons between suppliers or various application testings and cost effective at $99 US. Over 6,000 trial-sized antibodies are available to more than 3,300 protein targets, and new releases are continuing to be added every month.
Bethyl's purpose is to improve lives by supporting scientific discovery. This drives our complete dedication to the highest standards of product and service quality.